Company profile
Caribou Biosciences, Inc.
NASDAQ: CRBU · Healthcare · Biotechnology
#616 of 1,418 Healthcare companies by revenue57th-percentile growth
EA Score
43DFH 39DQ 47GM 43SS 49
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ listing tenure, operating margin
Methodology →Revenue TTM
$11.2M
Rev growth YoY (TTM)
+13.0%
Net income (FY)
-$148.1M
Employees
97
as of 2026-08-14
Market cap
$159.7M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$11.2M$11.2M2025
Net income-$148.1M-$148.1M2025
Operating income-$148.3M-$148.3M2025
Total assets$175.4M$175.4M2025
Liabilities$53.2M$53.2M2025
Equity$122.2M$122.2M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
UNITED STATES85%
Non-US15%
The read
What is Caribou Biosciences, Inc.’s revenue?
Caribou Biosciences, Inc. booked $11.2M in FY2025 revenue, growing 12% year over year — about the middle of the pack among Healthcare companies we track, at a -1327.4% net margin.
Peers · Healthcare
BIMI International Medical Inc.——Jaguar Health, Inc.38DNEXGEL, Inc.51DBellRock Brands Inc.——GSRX Industries Inc.——Veri Medtech Holdings Inc.46DNeighbors
Alameda →Key facts
CEORachel E. Haurwitz
SectorHealthcare
IndustryBiotechnology
HeadquartersBerkeley, CA
ExchangeNASDAQ: CRBU
Employees97
IPO date2021-07-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.